BioMarin Pharmaceutical Inc.

85.90-0.2900-0.34%Vol 895.85K1Y Perf -1.96%
Oct 4th, 2023 16:00 DELAYED
BID86.02 ASK88.61
Open86.33 Previous Close86.19
Pre-Market- After-Market85.90
 - -  - -%
Target Price
121.00 
Analyst Rating
Moderate Buy 1.82
Potential %
40.86 
Finscreener Ranking
★★     44.63
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★+     42.14
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★     57.36
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
14.42 
Earnings Rating
Strong Buy
Market Cap16.16B 
Earnings Date
25th Oct 2023
Alpha-0.00 Standard Deviation0.09
Beta0.36 

Today's Price Range

85.1586.56

52W Range

80.53117.77

5 Year PE Ratio Range

-487.5020.80

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-3.75%
1 Month
-5.33%
3 Months
-1.57%
6 Months
-11.05%
1 Year
-1.96%
3 Years
11.56%
5 Years
-15.03%
10 Years
16.36%

TickerPriceChg.Chg.%
BMRN85.90-0.2900-0.34
AAPL173.661.26000.73
GOOG136.272.97002.23
MSFT318.965.56501.78
XOM111.50-4.3300-3.74
WFC38.970.30000.78
JNJ155.520.18000.12
FB196.640.99000.51
GE108.851.09001.01
JPM143.350.64000.45
Financial StrengthValueIndustryS&P 500US Markets
3.30
5.10
0.19
0.24
7.40
Leverage Ratio 1.40
ProfitabilityValueIndustryS&P 500US Markets
76.30
5.80
10.90
-8.30
9.10
RevenueValueIndustryS&P 500US Markets
1.56B
8.39
5.88
9.42
Earnings HistoryEstimateReportedSurprise %
Q02 20230.240.3441.67
Q01 20230.240.3962.50
Q04 20220.120.11-8.33
Q03 20220.120.1633.33
Q02 20220.200.3365.00
Q01 20220.150.31106.67
Q04 2021-0.22-0.214.55
Q03 2021-0.12-0.0375.00
Earnings Per EndEstimateRevision %Trend
9/2023 QR0.2742.11Positive
12/2023 QR0.2812.00Positive
12/2023 FY1.2519.05Positive
12/2024 FY2.570.39Positive
Next Report Date25th Oct 2023
Estimated EPS Next Report0.27
Estimates Count11
EPS Growth Next 5 Years %-
Volume Overview
Volume895.85K
Shares Outstanding188.17K
Shares Float184.71M
Trades Count16.97K
Dollar Volume76.87M
Avg. Volume1.37M
Avg. Weekly Volume1.64M
Avg. Monthly Volume1.28M
Avg. Quarterly Volume1.19M

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) stock closed at 85.9 per share at the end of the most recent trading day (a -0.34% change compared to the prior day closing price) with a volume of 895.85K shares and market capitalization of 16.16B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 3059 people. BioMarin Pharmaceutical Inc. CEO is Jean-Jacques Bienaime.

The one-year performance of BioMarin Pharmaceutical Inc. stock is -1.96%, while year-to-date (YTD) performance is -17%. BMRN stock has a five-year performance of -15.03%. Its 52-week range is between 80.53 and 117.77, which gives BMRN stock a 52-week price range ratio of 14.42%

BioMarin Pharmaceutical Inc. currently has a PE ratio of 258.80, a price-to-book (PB) ratio of 4.42, a price-to-sale (PS) ratio of 12.77, a price to cashflow ratio of 114.60, a PEG ratio of 4.95, a ROA of 1.48%, a ROC of 1.59% and a ROE of 2.05%. The company’s profit margin is 9.10%, its EBITDA margin is 10.90%, and its revenue ttm is $1.56 Billion , which makes it $8.39 revenue per share.

Of the last four earnings reports from BioMarin Pharmaceutical Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.27 for the next earnings report. BioMarin Pharmaceutical Inc.’s next earnings report date is 25th Oct 2023.

The consensus rating of Wall Street analysts for BioMarin Pharmaceutical Inc. is Moderate Buy (1.82), with a target price of $121, which is +40.86% compared to the current price. The earnings rating for BioMarin Pharmaceutical Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

BioMarin Pharmaceutical Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

BioMarin Pharmaceutical Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 15.07, ATR14 : 1.92, CCI20 : -112.80, Chaikin Money Flow : 0.01, MACD : -0.81, Money Flow Index : 41.36, ROC : -2.23, RSI : 39.70, STOCH (14,3) : 6.40, STOCH RSI : 0.00, UO : 46.73, Williams %R : -93.60), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of BioMarin Pharmaceutical Inc. in the last 12-months were: Bienaime Jean (Option Excercise at a value of $14 952 105), Bienaime Jean (Sold 184 000 shares of value $18 024 984 ), Brian Mueller (Sold 0 shares of value $-952 914 ), Brian Mueller (Sold 17 380 shares of value $1 817 696 ), G. Eric Davis (Option Excercise at a value of $199 904), George Eric Davis (Option Excercise at a value of $99 952), Heron Elaine (Option Excercise at a value of $576 385), Jean-Jacques Bienaime (Sold 0 shares of value $-5 696 040 ), Jean-Jacques Bienaime (Sold 92 000 shares of value $9 361 492 ), Jeffrey R. Ajer (Sold 3 000 shares of value $258 360 ), Jeffrey Robert Ajer (Option Excercise at a value of $3 322 690), Jeffrey Robert Ajer (Sold 49 000 shares of value $5 668 937 ), Mark J. Alles (Buy at a value of $314 469), Richard A. Meier (Option Excercise at a value of $576 385), V. Bryan Lawlis (Sold 0 shares of value $-576 385 ), V. Bryan Lawlis (Sold 8 500 shares of value $825 265 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
14 (63.64 %)
13 (65.00 %)
13 (65.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
7 (31.82 %)
6 (30.00 %)
6 (30.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (4.55 %)
1 (5.00 %)
1 (5.00 %)
Summary RatingModerate Buy
1.82
Moderate Buy
1.80
Moderate Buy
1.80

BioMarin Pharmaceutical Inc.

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin has a hemophilia A gene therapy and a treatment for achondroplasia in late-stage clinical trials.

CEO: Jean-Jacques Bienaime

Telephone: +1 415 506-6700

Address: 770 Lindaro Street, San Rafael 94901, CA, US

Number of employees: 3 059

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

54%46%

Bearish Bullish

62%38%

 

TipRanks News for BMRN

Wed, 05 Jul 2023 05:05 GMT Positive Report for BioMarin Pharmaceutical (BMRN) from BMO Capital

- TipRanks. All rights reserved.

News

Stocktwits